Epizyme, Inc. (EPZM) Rating Increased to Sell at BidaskClub
BidaskClub upgraded shares of Epizyme, Inc. (NASDAQ:EPZM) from a strong sell rating to a sell rating in a report published on Saturday.
EPZM has been the topic of a number of other research reports. HC Wainwright restated a buy rating and set a $25.00 target price on shares of Epizyme in a report on Wednesday, June 7th. Royal Bank Of Canada set a $20.00 target price on Epizyme and gave the stock a buy rating in a report on Monday, June 12th. Zacks Investment Research upgraded Epizyme from a hold rating to a buy rating and set a $18.00 target price on the stock in a report on Tuesday, May 16th. Cann restated an outperform rating and set a $26.00 target price on shares of Epizyme in a report on Wednesday, April 12th. Finally, Wedbush reiterated an outperform rating and set a $24.00 price objective on shares of Epizyme in a report on Thursday, May 18th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have issued a buy rating to the company. The stock currently has an average rating of Buy and an average target price of $23.75.
Shares of Epizyme (EPZM) opened at 13.60 on Friday. The stock’s market capitalization is $793.67 million. The firm’s 50-day moving average is $13.86 and its 200-day moving average is $14.31. Epizyme has a 1-year low of $7.02 and a 1-year high of $18.50.
Epizyme (NASDAQ:EPZM) last issued its earnings results on Friday, August 4th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.56) by $0.08. Epizyme had a negative return on equity of 58.97% and a negative net margin of 1,376.33%. The firm had revenue of $10 million for the quarter, compared to analysts’ expectations of $3.95 million. During the same quarter last year, the business earned ($0.49) earnings per share. The company’s revenue was up 2027.7% compared to the same quarter last year. On average, analysts predict that Epizyme will post ($2.42) earnings per share for the current fiscal year.
In other Epizyme news, insider Peter Tai-Ching Ho sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $13.44, for a total value of $201,600.00. Following the sale, the insider now owns 22,228 shares in the company, valued at approximately $298,744.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Robert A. Copeland sold 2,500 shares of the business’s stock in a transaction that occurred on Tuesday, June 6th. The shares were sold at an average price of $13.45, for a total value of $33,625.00. Following the completion of the sale, the insider now owns 34,038 shares in the company, valued at approximately $457,811.10. The disclosure for this sale can be found here. Insiders sold a total of 50,524 shares of company stock worth $746,797 in the last 90 days. Company insiders own 25.20% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in EPZM. Legal & General Group Plc boosted its stake in Epizyme by 8.9% in the first quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock valued at $165,000 after buying an additional 795 shares during the last quarter. UBS Asset Management Americas Inc. bought a new position in Epizyme during the first quarter valued at $175,000. BB&T Securities LLC bought a new position in Epizyme during the second quarter valued at $181,000. Trexquant Investment LP bought a new position in Epizyme during the second quarter valued at $184,000. Finally, SG Americas Securities LLC raised its position in Epizyme by 83.3% in the second quarter. SG Americas Securities LLC now owns 13,364 shares of the biopharmaceutical company’s stock valued at $202,000 after buying an additional 6,072 shares during the period. Hedge funds and other institutional investors own 81.30% of the company’s stock.
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.